AVID ALERT: Bragar Eagel & Squire, P.C. is Investigating Avid Bioservices, Inc. on Behalf of Avid Stockholders and Encourages Investors to Contact the Firm
March 07, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Avid Bioservices, Inc....
SHAREHOLDER ALERT: Avid Bioservices Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
March 07, 2024 11:43 ET
|
Block & Leviton LLP
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Avid Bioservices, Inc. (NASDAQ: CDMO) for potential securities law violations. Investors who have lost money in their...
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
March 06, 2024 23:58 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
March 06, 2024 16:32 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it...
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
March 06, 2024 16:31 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023
March 06, 2024 04:00 ET
|
Rentschler Biopharma SE
Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United...
Pharmaceutical Quality Management Systems Markets: Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change, Training Management - Global Forecast to 2030
March 01, 2024 04:46 ET
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Quality Management Systems Market by Solution Type (Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change,...
Lipid Nanoparticles (LNPs) CDMO Market Players are mainly Focusing on the Nucleic Acids LNPs - Here's Why | 2024 Exclusive InsightAce Report
March 01, 2024 01:43 ET
|
InsightAce Analytic Pvt. Ltd.
Jersey City, NJ, March 01, 2024 (GLOBE NEWSWIRE) -- “The Lipid Nanoparticles (LNPs) CDMO Market” in terms of revenue was estimated to be worth $182.0 Mn in 2023 and is poised to reach $518.2 Mn by...
Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.
February 28, 2024 16:29 ET
|
Societal CDMO, Inc.
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to...
Berkshire Sterile Manufacturing Announces the Launch of Its Webinar Series, Perfecting Fill Finish
February 28, 2024 13:00 ET
|
Berkshire Sterile Manufacturing
Lee, MA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish CDMO and subsidiary of Sharp, will launch a webinar series, Perfecting Fill...